rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
Status: Not yet recruiting

A prospective, single center, randomized, clinical controlled study to evaluate the efficacy and prognosis differences between precision treatment based on plasma cfDNA testing results and the current conventional diagnostic and treatment practices for DLBCL patients.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age ≥ 18 years, gender not specified. Newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) confirmed by histopathological examination. Patients should test positive for plasma cfDNA before treatment (defined as positive for point mutations, CNV, IgH-related fusion, or IG clonal rearrangement) and achieve complete metabolic remission after 6 cycles of R-CHOP chemotherapy (evaluated by Lugano response assessment criteria). Patients for whom the researcher predicts a life expectancy of >6 months. Signed informed consent form.  Exclusion Criteria:  Patients who have undergone autologous stem cell transplantation. Patients with a history of other malignant tumors, except for basal cell carcinoma of the skin or in situ cervical cancer. Patients with uncontrolled cardiovascular diseases, coagulation disorders, connective tissue diseases, severe infectious diseases, and other such conditions; Primary central nervous system lymphoma. Patients with mental illness or others known or suspected to be unable to fully comply with the study protocol. Pregnant or lactating women. HbsAg-positive patients who need to undergo HBV-DNA testing and can only be included if they seroconvert. Additionally, if the HbsAg test is negative but the HBcAb test is positive (regardless of HbsAb status), HBV-DNA testing is also required. If the result is positive, inclusion is possible only after seroconversion. HIV-infected individuals. Other concurrent and uncontrolled diseases that researchers believe may affect the medical condition of patients participating in the study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Topical Nitro or Placebo Pre-Cath
Status: Not yet recruiting

Phase 2, single-center, randomized, blinded clinical study to assess the safety and efficacy of topical nitroglycerin on ease of TRA during scheduled PCI. We will compare topical nitroglycerin to placebo applied prior to planned, non-urgent PCI to determine if nitroglycerin is associated with decreased number of arterial puncture attempts made, decreased time to radial access, and lower crossover rate to TFA. Subjects will be randomized to receive either topical nitroglycerin ointment or placebo prior to scheduled PCI. There will be 256 subjects enrolled in this study with 1:1 randomization.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Male or non-pregnant female > 18 years of age at the time of consent Scheduled to undergo PCI using TRA in the cardiac catheterization laboratory Able to provide informed consent with capacity, given in English.  Exclusion Criteria  Patients with any of the following characteristics or conditions will not be included in the study:  Known nitrate allergy Allergy to CeraVe Moisturizing lotion Baseline hypotension with systolic blood pressure <90mmHg Absence of radial artery blood flow in one or both arms Presence or history of liver, rheumatologic, or chronic kidney disease Current treatment with any vasodilator therapy (eg. Sildenafil) Radial artery catheterization <30 days prior to enrollment Active site infection AV-fistula or prior radial artery harvest for bypass surgery - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fed Conditions in Healthy Adult Volunteers
Status: Recruiting

The objective of this clinical study is to compare the pharmacokinetics and the safety between a fixed-dose combination administration of "BR3005" and co-administration of "BR3005-1" and "BR3005-2" under fed conditions in healthy adult volunteers

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Those who have body mass index (BMI) within the range of 18.0 to 30.0kg/m² at screening visit  In case of a male subject, Those who weigh 50 kg or more In case of a female subject, Those who weigh 45 kg or more Those who sign written consent spontaneously after listening to and understanding sufficient explanation of the purpose and contents of this clinical trial, characteristics of the Investigational products, expected adverse events, etc.  Exclusion Criteria:  Those who have taken drugs that induce and inhibit metabolizing enzymes such as barbiturate within 30 days prior to the first day of administration or have taken drugs concerned about affecting this clinical trial within 10 days prior to the first day of administration. (however, participation is possible considering pharmacokinetics and pharmacodynamics such as Interaction of investigational products, half-life of concomitant drugs, etc.) Those who have participated in other clinical trials(including bioequivalence tests) and administered their investigational products within 6 months prior to the first administration date.(However, the termination for participation in other clinical trials are based on the last administration date of their investigational products) Those who have a medical history of gastrointestinal surgery or gastrointestinal diseases that may affect the absorption of drugs. (Except for simple appendectomy, hernia surgery) In the case of a female subject, those suspected pregnancy, pregnant woman, lactating woman. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 19 Years - StdAgeList: Adult, Older Adult
A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fasting Conditions in Healthy Adult Volunteers
Status: Recruiting

The objective of this clinical study is to compare the pharmacokinetics and the safety between a fixed-dose combination administration of "BR3005" and co-administration of "BR3005-1" and "BR3005-2" under fasting conditions in healthy adult volunteers

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Those who have body mass index (BMI) within the range of 18.0 to 30.0kg/m² at screening visit  In case of a male subject, Those who weigh 50 kg or more In case of a female subject, Those who weigh 45 kg or more Those who sign written consent spontaneously after listening to and understanding sufficient explanation of the purpose and contents of this clinical trial, characteristics of the Investigational products, expected adverse events, etc.  Exclusion Criteria:  Those who have taken drugs that induce and inhibit metabolizing enzymes such as barbiturate within 30 days prior to the first day of administration or have taken drugs concerned about affecting this clinical trial within 10 days prior to the first day of administration. (however, participation is possible considering pharmacokinetics and pharmacodynamics such as Interaction of investigational products, half-life of concomitant drugs, etc.) Those who have participated in other clinical trials(including bioequivalence tests) and administered their investigational products within 6 months prior to the first administration date.(However, the termination for participation in other clinical trials are based on the last administration date of their investigational products) Those who have a medical history of gastrointestinal surgery or gastrointestinal diseases that may affect the absorption of drugs. (Except for simple appendectomy, hernia surgery) In the case of a female subject, those suspected pregnancy, pregnant woman, lactating woman. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 19 Years - StdAgeList: Adult, Older Adult
Impulse Control Disorder Among Parkinson's Disease Patients
Status: Not yet recruiting

The goal of this observational study is to learn about impulse control disorders in Parkinson's disease patients.

The main question: it aims to answer:

Detect Relative frequency of impulse control disorder among Parkinson's disease patients
Detect Relation between impulse control disorders, and other non motor and motor symptoms in Parkinson's disease patients, using clinical, neurophysiological and radiological assessment

Eligibility:
- EligibilityCriteria: Inclusion criteria:  The study will include patients with Parkinson's disease, diagnosed according to the UK Parkinson's Disease Society Brain Bank criteria. (16) Bradykinesia (slowness of initiation of voluntary movements with progressive reduction in speed and amplitude of repetitive actions). And at least one of the following: Muscular rigidity, 4-6 Hz rest tremor Postural instability not caused by primary visual, vestibular, cerebellar or proprioceptive dysfunction  Exclusion criteria:  History of strokes with stepwise progression of Parkinsonian features. History of head injury. History of definite encephalitis. Oculogyric crises. Neuroleptic treatment at onset of symptoms. Strictly unilateral features after three years. Supranuclear gaze palsy. Cerebellar signs. Early severe autonomic involvement. Early severe dementia with disturbances of memory, language and praxis. Babinski sign. Presence of a cerebral tumor or communicating hydrocephalus on CT scan. Negative response to large doses of levodopa (if malabsorption excluded). - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with Parkinson's disease attending Assiut University neurology outpatient clinic and internal department - SamplingMethod: Probability Sample
Accelerated Theta Burst Stimulation for Treatment of Suicidality in Depressed Patients
Status: Recruiting

The objective of this study is to investigate efficacy of accelerated theta burst stimulation (TBS) in suicidal reduction in patients with unipolar and bipolar depression

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Diagnosis of Major depressive episode as a part of MDD or bipolar (I or II) disorder and confirmed by Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-I). (First & Gibbon.,2004 ). Meeting the severe depression cutoff for MADRS (>/=35) at baseline visit. Meeting the severe depression cutoff for BDI-II (>/=30) at baseline visit. Presence of suicidal ideation and/or behavior (confirmed with Columbia Scale for the Rating of Suicide Severity (C-SSRS) Adults (Age 19 years or older ) Right handedness Both genders Able to provide informed consent to participate in the study Participants were required to have been taking a stable pharmacological regimen for 2 weeks before screening. Pass the TMS adult safety screening (TASS) questionnaire  Exclusion Criteria  Current substance use disorder during the past 3 months Current psychotic disorder or symptoms Presence of dementia Presence of major medical illness, for example metastatic cancer, end stage renal disease Inability to verify contact information. Presence of any clinically significant neurological disorder, including organic brain disease, epilepsy, stroke, brain lesions, previous neurosurgery, or personal history of head trauma that resulted in loss of consciousness for > 5 minutes and retrograde amnesia for > 30 minutes Conductive, ferromagnetic or other magnetic sensitive metals that are implanted or are non-removable within 30 cm treatment coil (around the head) Presence of hypomanic symptoms (score on Young Mania Rating Scale (YMRS) greater than 12) Current severe insomnia (must sleep a minimum of 5 hours the night before stimulation) Using lorazepam greater than 2 mg daily (or equivalent) due to the potential to limit rTMS efficacy - HealthyVolunteers: No - Gender: All - MinimumAge: 19 Years - StdAgeList: Adult, Older Adult
The Appropriate Remifentanil Dose for Optimal Insertion of Laryngeal Mask Airway in Adult Patients During Induction of General Anesthesia Using Remimazolam.
Status: Recruiting

The laryngeal mask airway (LMA) is an airway maintenance device that is easy to insert and has the advantage of causing less sore throat and autonomic nervous system stimulation. To appropriately insert the LMA, an adequate depth of anesthesia is essential. Various drugs have been studied for inducing anesthesia to achieve the appropriate depth for LMA insertion, and the newly developed benzodiazepine, remimazolam, is gaining attention as one of them. Remimazolam has rapid onset and recovery times, hemodynamic stability, and is often co-administered with opioids like remifentanil for more effective LMA insertion. This study aims to find the optimal dose of remifentanil for the proper insertion of the Ambu Auragain, one of the recently developed LMAs, during induction of anesthesia using remimazolam and the Biased-Coin Up-and-Down method will be used for this purpose. Starting with an initial concentration of remifentanil of 3.0 μg/mL, the success or failure of LMA insertion will determine the dosage for the next subject. Data will be collected from a total of 60 patients, and subsequent analysis will be conducted.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients aged 19 years or older and less than 65 years ASA physical status classification I, II, or III Scheduled for elective surgery lasting within 3 hours under general anesthesia using a laryngeal mask  Exclusion Criteria:  Refusal to participate in the study Unable to read the consent form or comprehend the research process (e.g., illiteracy, foreign nationality, cognitive impairment) Anatomic structures that are anticipated to cause difficulty in mask ventilation History of difficulty in airway management Upper respiratory infections or respiratory conditions (e.g., asthma, pneumonia) Risk of aspiration (e.g., gastroesophageal reflux) Allergies to anesthesia-related drugs, such as benzodiazepines or opioid analgesics Impaired liver or kidney function Pregnant or breastfeeding patients Obesity (body mass index > 30 kg/m2) History of drug or alcohol abuse. - HealthyVolunteers: No - Gender: All - MinimumAge: 19 Years - MaximumAge: 64 Years - StdAgeList: Adult
The Application of Probe Confocal Laser Endomicroscopy in Pancreatic Tumor Surgery
Status: Recruiting

Aim of the study: To evaluate the value of Probe Confocal Laser Endomicroscopy (PCLE) in surgery for pancreatic tumor.

Methods:

Patients who are diagnosed with pancreatic tumor based on preoperative radiographic findings and will undergo radical resection are included in this clinical study. PCLE will be used in surgery to identify tumor is malignant or not, and surgeons will decide procedures of surgery based on outcomes of PCLE. In this present study, clinical trials will be divided into two phases. In the first phase, based on the definitive postoperative pathologic diagnosis, characteristic imaging structures that were collected by PCLE will be identified and primary diagnostic imaging criteria for pancreatic cancer would be developed. In the second phase, this criterion will be used for rapid intraoperative diagnosis of pancreatic cancer and predicting status of resection margin. In addition, accuracy of PCLE will be verified based on postoperative pathologic reports.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  patients are diagnosed with pancreatic neoplasms based on preoperative radiographic findings and auxiliary examination results, and they will undergo pancreatoduodenectomy or distal pancreatectomy. Patients who have no serious abnormalities of blood system, heart and lung function and immune deficiency and can tolerate surgery. Patients who are not allergic to fluorescein sodium will be included.  Exclusion Criteria:  Patients accompanied by other systemic malignancies. Central nervous system disease, mental disease, unstable angina pectoris, congestive heart failure, serious arrhythmia and other uncontrollable serious diseases, unable to tolerate surgery. Patients who have had definitive pathologic diagnosis before surgery will be excluded. Any condition that may impair the safety of patients or the integrity of research data, including serious medical risk factors, medical conditions, and laboratory abnormalities. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 90 Years - StdAgeList: Adult, Older Adult
Erector Spinae Plane (ESP) Block vs Intravenous Lignocaine Infusion in (VATS)
Status: Not yet recruiting

The goal of this clinical trial is to compare analgesic efficacy of erector spinae plane (ESP) block vs intravenous lignocaine infusion in video- assisted thoracoscopy (VATS. The main goals are to compare post- operative pain scores and cumulative post- operative opioid doses in both groups

Eligibility:
- EligibilityCriteria: Inclusion criteria:  Age >18 VATS for tumor resection or partial lung resection in emphysema Written, informed consent obtained 1 day prior to surgery  Exclusion criteria:  Lack of consent for ESP blockade History of allergy to local anaesthetics Other contraindications to ESP blockade American Society of Anesthesiologists(ASA) Physical Status Classification value 4 or higher VATS for indications other than tumor resection or partial lung resection in emphysema Insulin- dependent diabetes mellitus More than 1 chest drain post-operatively Conversion to thoracotomy Chronic opioid use prior to surgery defined as opioid administration for at least 3 months during the last 12 months History of alcohol abuse Suspected technical difficulties with performing the ESP block (e.g. obesity) Inadequate spread of the local anaesthetic during the ESP block Cognitive impairment that might cause an inaccurate assessment of pain levels - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Aortic Remodeling After Endovascular Management of Type B Aortic Dissection.
Status: Not yet recruiting

Assess the clinical outcome, morphological changes and behaviour of type B aortic dissection after endovascular repair.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Complicated Stanford type B dissections:  Rupture. malperfusion (visceral, extremities or spinal cord ischemia).  High-risk aortic dissections:  Refractory pain, refractory hypertension or bloody pleural effusion. High-risk radiographic features (max. aortic diameter >40mm, false lumen diameter >22mm, 1ry entry tear >1cm, entry tear location on the lesser curve and radiographic only malperfusin).  Aortic anatomy suitable for stent graft therapy:  Proximal landing zone (diameters between 15 and 42mm, measured form outer wall to outer wall) isn't aneurysmal, dissected or significantly thrombosed. Proximal landing zone length ≥20mm. Radius of curvature ≥20mm for aortic arch landing zones. Arch or distal aortic angulation 45≤ degrees. Compatible Iliac and/or femoral access vessel morphology (diameter and tortousity) that allows endovascular access to the dissection site with the delivery system of the appropriately sized device, with or without the use of either surigcal or endovascular conduit. Age ≥18yrs. Life expectancy >2yrs  Exclusion Criteria:  Known hypersensitivity to device component or contraindication to anticoagulation or contrast media. Systemic or local infection that may increase the risk of endovascular graft infection. Subjects with past descending or abdominal aortic interventions. Un-correctable coagulopathy Active vasculitis Inability or refusal to give informed consent by subject or legal representative Subject is unwilling to comply with the follow-up schedule. - Gender: All - MinimumAge: 18 Years - MaximumAge: 85 Years - StdAgeList: Adult, Older Adult - StudyPopulation: complicated or high-risk acute, subacute or chronic type B aortic dissection. - SamplingMethod: Non-Probability Sample
The Effect of Aromatherapy Application With Bergamot and Grapefruit Essential Oils on PMS
Status: Recruiting

Aromatherapy is;the science of using highly concentrated essential oils or essences distilled from plants to take advantage of their therapeutic properties. Essential oils or essences are obtained from various parts of plants (root, leaf, flower, bark, fruit) and used therapeutically for physical and psychological well-being.

Premenstrual syndrome (PMS) is a health problem characterized by the periodic occurrence of physical, cognitive, emotional and behavioral symptoms during the luteal phase of the menstrual cycle, ending with the onset of menstruation or with the alleviation of symptoms within a few days after the onset of menstruation. It is reported that approximately 80-95% of women complain of PMS complaints.

Although the use of aromatherapy in womens health is widespread, there is no study comparing bergamot and grapefruit essential oils. The aim of this study was to determine the effect of aromatherapy with bergamot and grapefruit essential oils on premenstrual syndrome and menstrual symptoms.

Eligibility:
- EligibilityCriteria: Inclusion Criteria  To be between the ages of 18-35 Experiencing at least 5 of the pms complaints (self-report) Not having respiratory diseases such as asthma and bronchitis (self-report) No pregnancy or suspected pregnancy (self-report) Not being allergic to any substance (self-report) Not having a systemic disease such as diabetes, hypertension (self-report)  Exclusion Criteria:  Under 18, over 35 years of age Not experiencing pms complaints Finding anosmia Presence of respiratory system diseases Allergic symptoms to aromatherapy Being pregnantHaving a chronic disease - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - MinimumAge: 18 Years - MaximumAge: 35 Years - StdAgeList: Adult
ICF in Takayasu Arteritis
Status: Recruiting

The aim was to analyze the problem in patients with Takayasu Arteritis based on the International Classification of Functioning, Disability and Health.The sample of our study will consist of individuals between the ages of 18-65 who have been diagnosed with Takayasu Arteritis by rheumatologists and are followed by Pamukkale University Rheumatology Clinic.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:-Being between the ages of 18-65  Volunteering to participate in the study Being diagnosed with Takayasu Arteritis by a rheumatologist  Exclusion Criteria:- Having another disease that affects your physical condition  Having cognitive impairment that makes it difficult to cooperate Being pregnant Having a neurological disease Having had any surgery in the last year Having another concurrent rheumatic disease - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult